Because of the rarity of hepatic vein tumor thrombus (HVTT) compared with portal vein tumor thrombus (PVTT) in patients with hepatocellular carcinoma, little is known about this disease entity. The aim of this study was to evaluate the prognosis of each treatment modality for HVTT through an analysis of data collected in a Japanese nationwide survey. We analyzed data for 1,021 Child-Pugh A hepatocellular carcinoma patients with HVTT without inferior vena cava invasion registered between 2000 and 2007. Of these patients, 540 who underwent liver resection (LR) and 481 who received other treatments were compared. Propensity scores were calculated, and we successfully matched 223 patients (49.0% of the LR group). The median survival time in the LR group was 2.89 years longer than that in the non-LR group (4.47 versus 1.58 years, P < 0.001) and 1.61 years longer than that in the non-LR group (3.42 versus 1.81 years, P 5 0.023) in a propensity score-matched cohort. After curative resection, median survival times were similar between patients with HVTT in the peripheral hepatic vein and those with HVTT in the major hepatic vein (4.85 versus 4.67 years, P 5 0.974). In the LR group, the postoperative 90-day mortality rate was 3.4% (16 patients). In patients without PVTT, the median survival time was significantly better than that in patients with PVTT (5.67 versus 1.88 years, P < 0.001). Conclusion: LR is associated with a good prognosis in hepatocellular carcinoma patients with HVTT, especially in patients without PVTT. (HEPATOLOGY 2017;66:510-517).
A ccording to the American Association for the Study of Liver Diseases/Barcelona Clinic for Liver Cancer staging system and treatment guidelines, hepatocellular carcinoma (HCC) associated with macroscopic vascular invasion is regarded as an advanced stage of disease with almost zero hope for a cure.
(1) The only proposed treatment option for this group of patients is palliative sorafenib chemotherapy. (2) However, the reported median survival time (MST) of patients with macroscopic vascular invasion treated with sorafenib is as short as 8.1 months.
Recently, we reported that the survival benefit of liver resection (LR) in HCC patients with portal vein tumor thrombus (PVTT) is significant, resulting in an MST of 2.87 years with a 5-year survival rate of 39.1% in a Japanese nationwide survey. (4) Therefore, surgical intervention might also play some role in the treatment of patients with hepatic vein tumor thrombus (HVTT).
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Because of its rarity, compared with PVTT, little is known about HVTT. As a result of recent advances in surgical techniques and perioperative management, aggressive surgical resection for HCC with HVTT has been proposed by several tertiary centers. (5) (6) (7) (8) Recently, a member of our group reported the largest singlecenter case series of patients with HVTT who had undergone LR, resulting in an MST of longer than 4 years. (5) However, the number of patients enrolled in such studies is generally too small to lead to a definite conclusion.
The aim of this study was to evaluate the survival benefit of LR for HCC patients with hepatic vein invasion through analysis of a large-scale prospective cohort study based on the latest data available from a Japanese nationwide survey.
Patients and Methods

PATIENTS
Since 1965, the Liver Cancer Study Group of Japan has been performing nationwide surveys of patients with primary liver cancer. Patients are registered and followed up as reported. (9) The collection and registration of data for patients with HCC were performed with the approval of each institution participating in the nationwide survey. The number of registered institutions was 645, accounting for approximately one third of all HCC patients treated in Japan. To analyze the recent results, we set the study period from 2000 to 2007 (latest data available). The presence of HVTT and PVTT was determined based on the radiological findings. HVTT was categorized as tumor thrombosis in a peripheral hepatic vein (pHVTT, Vv1), in a major hepatic vein (mHVTT, Vv2), or in the inferior vena cava (IVCTT, Vv3); and PVTT was categorized into main trunk/contralateral branch (Vp4), first-order branch (Vp3), second-order branch (Vp2), and thirdorder branch (Vp1), according to the Japanese staging system. (10) Postoperative mortality was defined as any death other than tumor progression within 90 days of surgery.
STATISTICAL ANALYSIS
Statistical analyses were performed using JMP software, version 12.2.0 (SAS Institute Inc., Cary, NC). Categorical variables were analyzed using the chi-squared test. Continuous variables were analyzed using the Wilcoxon rank-sum test. Overall survival curves were determined using the Kaplan-Meier method and compared using the log-rank test. Propensity scores were created using logistic regression modeling of the probability of a patient undergoing LR based on age, sex, viral infection (hepatitis B and/or C virus), positive serum alpha-fetoprotein (15 ng/mL), serum albumin (grams per deciliter), log 10 (total bilirubin) (milligrams per deciliter), prothrombin time (percentage), platelet count (10 4 per microliter), gastroesophageal varices, multiple tumors (three or more), tumor size (centimeters), extent of HVTT, and presence of PVTT (Vp2-3). Because the log 10 (total bilirubin) tended to show a normal distribution for the entire cohort compared to serum total bilirubin level, this parameter was used instead (Supporting Fig. S1 ). A 1:1 match without
replacement was performed using logit (propensity score) through the nearest available matching, setting the caliper at 0.05. A multivariate analysis was performed using a Cox proportional hazards model and the backward elimination procedure. P < 0.10 was set as the cutoff value for the elimination. The following nine variables were examined as potential risk factors: age >70 years, gastroesophageal varices, platelet count <100,000/lL, positive serum alphafetoprotein (15 ng/mL), number of tumors 3, tumor size (centimeters), presence of PVTT (Vp2-3), mHVTT, and LR. Liver cirrhosis and poor cancer cell differentiation were also examined in patients who underwent LR. All statistical analyses were twotailed. P < 0.05 was considered to indicate statistical significance. Of the 1,266 patients with HVTT, 651 underwent LR (LR group) and 615 received other treatments (non-LR group). In the non-LR group, 335 patients (54.5 %) received transcatheter arterial chemoembolization (TACE), 143 patients (23.3%) received systemic or hepatic arterial infusion chemotherapy, 50 patients (8.1%) received ablation therapy, 69 (11.2%) patients received best supportive care, and 18 patients (2.9%) underwent other treatments. Because sorafenib was only available after 2009 in Japan, none of the patients received sorafenib as an initial treatment. (Fig. 1A) . The survival rates at 1, 3, and 5 years after diagnosis were 80.0%, 56.6%, and 44.2% for the LR group and 63.7%, 32.6%, and 20.3% for the non-LR group, respectively. In the non-LR group, the MST after diagnosis according to treatments was as follows: TACE, 1.61 years (95% CI 1.29-2.01); systemic or hepatic arterial infusion chemotherapy, 0.87 years (95% CI 0.74-1.13); and best supportive care, 0.52 years (95% CI 0.24-0.95). A multivariate analysis performed to determine the risk factors for overall survival also identified non-LR treatment (hazard ratio [HR] 5 1.61, 95% CI 1.30-2.01; P < 0.001) as one of the most significant risk factors (Supporting Table S1 ). The reason for death is shown in Supporting Table S2 . The frequency of non-cancer-related deaths was comparable in the two groups (10.6% versus 11.9%, P 5 0.512), and the median cancer-specific survival time for the LR group was 3.91 years longer than that for the non-LR group (6.12 years, 95% CI 4.78-not available, versus 2.21 years, 95% CI 1.81-2.85; P < 0.001) (Supporting Fig. S2 ).
Results
On the other hand, in IVCTT patients, the MST after diagnosis for the LR group was 0.64 years longer than that for the non-LR group (1.48 years, 95% CI 1.16-2.52, versus 0.84 years, 95% CI 0.61-1.07; P < 0.001) (Fig. 1B) . The survival rates at 1 and 3 years after diagnosis were 63.2% and 33.1% for the LR group and 42.3% and 20.1% for the non-LR group, respectively. In the non-LR group, the MST after diagnosis according to treatments was as follows: TACE, 0.84 years (95% CI 0.58-1.17); systemic or hepatic arterial infusion chemotherapy, 1.28 years (95% CI 0.51-2.41); and best supportive care, 0.49 years (95% CI 0.18-0.93).
To confirm the survival benefit of LR in ChildPugh A patients with pHVTT/mHVTT, the propensity scores were calculated for 455 patients in the LR group and 380 patients in the non-LR group. We successfully matched 223 patients in the LR group (49.0% of the LR group) and 223 patients in the non-LR group (58.7% of the non-LR group) based on their propensity scores. In the non-LR group, 126 patients (56.5 %) received TACE, 38 patients (17.0%) received systemic or hepatic arterial infusion chemotherapy, 37 patients (16.6%) received ablation therapy, 15 (6.7%) patients received best supportive care, and 7 patients (3.1%) underwent other treatments. Table 2 shows that the main characteristics of these patients did not differ between the two groups. The MST after diagnosis in the LR group was 1.61 years longer than that in the non-LR group (3.42 years, 95% CI 2.40-4.47, versus 1.81 years, 95% CI 1.48-2.48; P 5 0.023) (Fig.  1C) . Furthermore, the survival rates at 1, 3, and 5 years after diagnosis were 75.6%, 51.8%, and 33.1% for the LR group and 67.1%, 37.0%, and 27.9% for the non-LR group, respectively.
The operative procedures and outcomes of the patients in the LR group who underwent curative resection according to the extent of HVTT are shown in Table 3 . Major hepatectomy was the most frequent procedure for all types of HVTT. The MST after surgery according to the extent of HVTT was as follows: pHVTT, 4.85 years (95% CI 3.38-not available); mHVTT, 4.67 years (95% CI 3.32-5.88); and IVCTT, 1.37 years (95% CI 1.07-4.21). The survival curves were similar between patients with pHVTT and those with mHVTT ( Fig. 2A) . The recurrence-free survival after surgery according to the extent of HVTT was as follows: pHVTT, 2.36 years (95% CI 1.38-3.17); mHVTT, 0.88 years (95% CI 0.75-1.32); and IVCTT, 0.82 years (95% CI 0.42-1.10). The most frequent site of recurrence was intrahepatic for patients with pHVTT and mHVTT, whereas distant metastasis was the most frequent site for patients with IVCTT. The postoperative 90-day mortality rate was 4.2% (23 patients) for the entire population and was higher for patients with IVCTT (pHVTT, 4.3%; mHVTT, 1.8%; IVCTT, 9.9%). A multivariate analysis performed to determine the risk factors for overall survival after LR in patients with pHVTT/mHVTT identified the presence of PVTT (Vp2-3) (HR 5 1.91, 95% CI 1.34-2.70; P < 0.001), number of tumors 3 (HR 5 1.88, 95% CI 1.28-2.71; P 5 0.002), gastroesophageal varices (HR 5 1.85, 95% CI 1.13-2.90; P 5 0.016), and poor cancer cell differentiation (HR 5 1.57, 95% CI 1.02-2.35; P 5 0.040) as significant risk factors (Table 4 ). In patients without PVTT (Vp2-3), the MST was significantly better than (Fig. 2B ).
Discussion
The current study revealed that LR has a significant survival benefit with an acceptable postoperative mortality rate for patients with HVTT, even in the propensity score-matched patient groups. Coexisting PVTT was a significant risk factor for survival after LR, and patients without PVTT had an MST of more than 5 years. These results indicate that HVTT is different from PVTT and should not be considered as an advanced stage for palliative treatment.
A worldwide consensus on the management of HCC associated with macroscopic vascular invasion does not yet exist. Surgical resection has been performed successfully in patients with PVTT in Eastern countries, (7, 11) and several reports arising from Western countries also discuss this approach. (8, 12) On the other hand, little is known about HVTT. This lack of knowledge is probably because HVTT is relatively rare, compared with PVTT, in patients with HCC. (13) Indeed, in this nationwide survey, hepatic vein invasion was observed in only 4.5% of the entire population. As a result, most studies have reported the results for HVTT together with those for PVTT, and studies focusing on HVTT alone have been rare. (3, 7, 14) Thus, the poor prognosis of macroscopic vascular invasion may be highly affected by the population with PVTT, and the results concerning patients with HVTT might not have been correctly evaluated. Considering that the MST after LR was more than 4 years in patients with HVTTs and more than 5 years in patients without PVTT, HVTT per se is different from PVTT. As a prospective trial other than a nationwide survey would be difficult to conduct because of the rarity of this disease, the present study provides the highest level of evidence available regarding this issue.
Surgical treatment for HVTTs is technically demanding, and a major hepatectomy is often required. The 90-day mortality rate was higher in patients with HVTT than in those without (3.4% versus 1.2%, P < 0.001). However, there was no difference between the two groups in patients who underwent major hepatectomy (3.3% versus 2.0%, P 5 0.147). These results are comparable with those of other reports. (15, 16) In addition, although complication data were not available, the postoperative hospital stay was also comparable to that reported in a previous Japanese nationwide survey. (15) Thus, the present findings justify the consideration of surgical treatment for HCC patients with HVTT.
Sorafenib has been established as a new standard treatment option for advanced HCC. (1, 2) The effectiveness of sorafenib for HCC patients with macroscopic vascular invasion has also been reported. (3) Since sorafenib became available in Japan in 2009, hardly any patients received it during the presently reported study period. Therefore, the prognosis of the non-LR group might be slightly better now, thanks to the introduction of sorafenib. However, sorafenib is essentially a palliative treatment; and the expected survival time is normally no longer than 1 year in patients with macroscopic vascular invasion, and the average prolongation of survival is 3.2 months. (3) Considering that the MST was more than 4 years and the average prolongation of survival was 2.89 years in the LR group, the survival benefit of LR in patients with HVTT is likely to exist even in the present era of sorafenib treatment.
Available evidence regarding the most suitable treatment strategies for IVCTT is extremely limited because of the rarity of the disease. Indeed, in our nationwide surveillance, the frequency of IVCTT was as small as 1.4%. Surgical resection for IVCTT patients has been reported to result in an MST similar to that in the present report. (5, 13) However, considering that complete resection is difficult in IVCTT patients and the MSTs were similar between the LR group and the chemotherapy group (1.48 versus 1.28 years), the surgical indications for IVCTT patients require further investigation and comparison with sorafenib treatment. Furthermore, neoadjuvant and/or adjuvant treatment including sorafenib and/or radiotherapy together with LR might be a promising strategy for IVCTT patients. (17, 18) In a comparison between the IVCTT and mHVTT groups, while the recurrence-free survival was similar, the MST was significantly poorer in the IVCTT group. This finding can be explained by differences in the sites of recurrence (Table 3 ). In the mHVTT group, the most frequent type of recurrence was intrahepatic limited recurrence (63.8%), while distant metastasis and/or intrahepatic recurrence were the most common sites in the IVCTT group (58.5%). As long as the recurrence is confined to the liver, at least one of several effective treatment options can be selected, including repeated LR, radiofrequency ablation, and TACE. Therefore, HVTT by itself is not a systemic disease, and control of intrahepatic recurrence should be undertaken in these cases as in cases of HCC without vascular invasion. Furthermore, aggressive surgical treatment might be justifiable for HVTT to avoid progression to IVCTT, which can be considered a systemic disease in which distant metastasis is likely to occur frequently. These results were similar to those of our recent single-center report. (5) Concerning other treatment modalities for HVTT, the MSTs were similar in HVTT patient groups treated with TACE (1.61 versus 1.38 years), chemotherapy (0.87 versus 0.88 years), and best supportive care (0.52 versus 0.36 years) compared with those in PVTT patient groups. (4) On the other hand, the MST was significantly better in patients with HVTT than in those with PVTT after LR (4.47 versus 2.87 years), indicating that the survival benefit of LR is more significant among patients with HVTT than among those with PVTT. Recently, yttrium-90 radioembolization and other new radiation procedures have produced favorable outcomes in patients with macroscopic vascular invasion. (19) (20) (21) (22) However, such studies are not specified for patients with HVTTs, and future study is essential.
One of the limitations of our study was that although we tried to eliminate the selection bias of the LR group through propensity score-based matching, the possibility of other biases that were not considered in the present study certainly exists. To the best of our knowledge, this is the largest case series to be reported for HVTT. Considering that the MST was more than 4 years after LR, LR should be considered for patients with HVTT before resorting to palliative treatment, including sorafenib. Another limitation is that, although this article demonstrated a survival benefit of LR in HCC patients with HVTT using data from a nationwide survey, the study was limited to patients in Japan, and the etiology of HCC in Japan is mainly viral infection, especially infection with the hepatitis C virus. Thus, these results should be validated using an international database.
Another limitation is the low frequency of HVTT in the entire HCC population. Particularly, patients who are considered to show the most benefit from surgical resection, i.e., those without IVCTT or PVTT, are estimated to be a small proportion. However, due to its rarity, evidence concerning this disease entity is scarce, and a prospective trial is theoretically difficult. Although the number is small, the present report would certainly contribute to prolonging the survival in some patients who suffer from HCC with HVTT.
In conclusion, LR is associated with a good prognosis, with an MST of more than 4 years in HCC patients with HVTT. As long as the hepatic vein invasion is limited to the major hepatic veins, LR should be the treatment of first choice, especially in patients with good liver function.
